Pharmacological Treatments for Panic Disorder

Panic disorder is characterised by recurrent, unexpected panic attacks and persistent concern about future episodes. Pharmacological interventions form a cornerstone of management, typically involving first-line agents such as selective serotonin reuptake inhibitors (SSRIs) and serotonin–noradrenaline reuptake inhibitors (SNRIs). These agents mitigate panic symptoms by enhancing monoaminergic neurotransmission and reducing amygdala hyperactivity. Benzodiazepines constitute a rapid-onset alternative, acting as positive allosteric modulators at the GABAA receptor to produce anxiolytic effects, though their use is often limited by tolerance, dependence and withdrawal. Tricyclic antidepressants, exemplified by imipramine, offer another established option but carry a less favourable side-effect profile. Novel avenues under exploration include modulators of the glutamatergic system, neurokinin antagonists and compounds targeting the endocannabinoid system. Treatment selection balances efficacy, onset of action and safety, with long-term maintenance tailored to individual risk factors, comorbidities and patient preference. Globally, these treatments have demonstrated consistent reductions in attack frequency, anticipatory anxiety and functional impairment, underscoring their practical significance in clinical practice.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Treatments for Panic Disorder publication trend

The graph below shows the total number of articles in pharmacological treatments for panic disorder across all publications each year (not limited to Nature Index journals).

Technical terms

Selective serotonin reuptake inhibitor (SSRI): A drug class that increases synaptic serotonin by inhibiting its reabsorption into presynaptic neurones, commonly used as first-line therapy in panic disorder.

Benzodiazepine: A class of compounds that enhance GABAA receptor activity to produce rapid anxiolysis, with risks of tolerance and dependence.

Azapirone: A non-benzodiazepine anxiolytic acting as a partial agonist at serotonin 5-HT1A receptors, noted for lower sedation and dependence potential.

Panic attack: A sudden onset of intense fear or discomfort accompanied by physical symptoms such as palpitations, sweating and shortness of breath.

References

1. Tratamiento farmacológico del trastorno de pánico. Revista de Neuro-Psiquiatría (2013).
2. Evidence from Cochrane systematic reviews on pharmacological treatment compared to placebo for panic disorder. Dementia & Neuropsychologia (2022).
3. Efficiency of fluoxetine and alprazolam in the treatment of panic disorder. Theoretical and Natural Science (2024).
4. How pharmacology can aid in the diagnosis of mental disorders. Naunyn-Schmiedeberg's Archives of Pharmacology (2024).